New Drug Application Submitted for ALS Drug
Edaravone previously granted Orphan Drug Designation by the FDA for amyotrophic lateral sclerosis.
A New Drug Application (NDA) was recently submitted to the FDA for edaravone (MCI-186) in the treatment of amyotrophic lateral sclerosis (ALS).
The NDA submission is Mitsubishi Tanabe Pharma Corporation’s (MTPC) first step in accelerating its US business activities as part of their Medium-Term Management Plan 16-20: Open up the Future, the company noted in a press release.
Thus far, MTPC has established MT Pharma America, Inc to commercialize approved drug products in the United States as a part of their management plan, with future goals to expand its product line by collaborating with partners.
“There is an urgent need for new treatment approaches that may affect the course of this devastating disorder,” said Lucie Bruijn, PhD, MBA, Chief Scientist at The ALS Association. “The ALS Association is encouraged by the efforts of Mitsubishi Tanabe Pharma to make this drug available to people living with ALS in the US.”
In 2015, edaravone was approved to treat ALS in Japan and South Korea and was also granted Orphan Drug Designation by the FDA and European Commission.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025